Lipocine's Oral PPD Drug LPCN 1154 Misses Phase 3 Primary Endpoint
Lipocine's oral postpartum depression drug LPCN 1154 failed to meet its primary endpoint in a Phase 3 trial involving 90 patients. However, a post hoc analysis showed clinically meaningful improvements in a subset of 54 patients with psychiatric history, and the drug demonstrated a favorable safety profile supporting outpatient use.
Lipocine Inc.'s oral postpartum depression drug LPCN 1154 failed to meet its primary endpoint in a Phase 3 clinical trial, though it showed promising results in a subset of patients with psychiatric history. The drug demonstrated a favorable safety profile with no treatment-related serious adverse events reported.
In the Phase 3 study population of 90 patients with postpartum depression, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60, meaning the primary endpoint was not met. However, in a post hoc analysis of 54 participants who had a history of psychiatric conditions, LPCN 1154 demonstrated nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained through day 30.
In the overall population, LPCN 1154 was well tolerated and demonstrated a differentiated safety profile with no reported adverse event, including somnolence or dizziness, occurring in more than 5% of the LPCN 1154-treated participants. No treatment-related severe or serious adverse events were reported, and no cases of excessive sedation or loss of consciousness were observed. The favorable safety profile supports outpatient administration without the need for healthcare provider monitoring.
The randomized, double-blind, placebo-controlled study enrolled a total of 90 patients with severe postpartum depression, having an average baseline Hamilton depression rating scale of 28.3. LPCN 1154 has shown a positive safety profile, with all reported nervous system adverse events being mild to moderate in severity. Furthermore, there were no instances of drug discontinuation, excessive sedation, loss of consciousness, or drug-related serious adverse events.
The company plans to evaluate all available options going forward and has applied for FDA breakthrough therapy and fast track designations. Data from this Phase 3 trial are expected to support a 505(b)(2) NDA submission for LPCN 1154 in 2026.
LPCN 1154 is an oral formulation of brexanolone being developed to provide rapid relief of postpartum depression in a convenient, at-home treatment. It has potential as first line treatment choice for women with postpartum depression and characteristics that could be particularly beneficial to patients with severe postpartum depression for whom rapid improvement is a priority.